# Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk

> **NCT03000335** · — · UNKNOWN · sponsor: **Curewize Health Ltd.** · enrollment: 65 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03000335
- **Lead sponsor:** Curewize Health Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2020-05
- **Final completion:** 2021-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03000335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03000335, "Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03000335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*